Uta S.
- Country
- Germany
- Department
- na
Research Overview
- J3L-MC-EZEB: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3819469 in Adults with Elevated Lipoprotein(a)
- A Randomized, Placebo‑Controlled Trial of Zenagamtide (NNC0487‑0111) in Obese Patients with HFpEF or HFmrEF to Reduce CV Death and HF Hospitalization
- Phase III Randomized Double‑Blind Study of Elecoglipron Plus Dapagliflozin Versus Elecoglipron or Dapagliflozin Monotherapy in Adults with Type 2 Diabetes Mellitus
Data & Insights
Has run more than one trial at 41 of 417 partner sites.
Specializations
Cardiovascular Research
The investigator specializes in heart failure prevention and management of cardiovascular risks, with particular focus on innovative therapeutic combinations for patients at elevated risk of cardiac events.
- Heart Failure Prevention Strategies
- Cardiovascular Death Risk Reduction
- Combination Therapy Approaches
The research extends to evaluating novel therapeutic agents for cardiovascular risk management.
Metabolic Disorders
Key research interests include the management of Type 2 Diabetes Mellitus and investigation of advanced therapeutic options for glycemic control.
- Diabetes Treatment Optimization
- Glycemic Control Strategies
- Treatment Switching Protocols
Focus includes evaluation of innovative diabetes medications and their impact on cardiovascular outcomes.
Lipid Management
The investigator conducts research in lipoprotein disorders, specifically focusing on therapeutic interventions for elevated Lipoprotein(a) levels.
- Lipoprotein Reduction Strategies
- Novel Lipid-Lowering Therapies
- Cardiovascular Risk Modification
Research emphasis includes evaluation of emerging treatments for lipid disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.